

FIN 1632

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Fallaux et al.

Serial No.: 10/038,271

Filed: October 23, 2001

For: PACKAGING SYSTEMS FOR

HUMAN RECOMBINANT ADENOVIRUS

TO BE USED IN GENE THERAPY

Confirmation No.: 8381

Examiner: D. Nguyen

Group Art Unit: 1632

Attorney Docket No.: 2578-3833.6US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail on the date of deposit shown below with sufficient postage and in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 5, 2004

Date

Aubry Blackburn

Name (Type/Print)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as

Serial No.: 10/038,271

defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56 (b) exists.

U.S. Pate	nt Documents
-----------	--------------

U.S. Patent No.	Publication Date	Patentee
US - 6,051,430	04-18-2000	Plasterk et al.
US - 6,140,103	10-31-2000	Einerhand et al.
US - 6,204,052	03-20-2001	Bout et al.
US - 6,232,105	05-15-2001	Einerhand et al.
US - 6,238,893	05-29-2001	Hoeben et al.
US - 6,265,212	07-24-2001	Fallaux et al.
US - 6,203,975	03-2001	Wilson
US - 6,306,652 B1	10-23-2001	Fallaux et al.
US - 6,602,706 B1	08-05-2003	Fallaux et al.
US - 2002/0102732 A1	08-01-2002	Fallaux et al.
US - 2002/0173039 A1	11-02-2002	Fallaux et al.
US - 2003/0104626 A1	06-05-2003	Fallaux et al.
US - 2002/0164802 A1	11-07-2002	Fallaux et al.
US- 6,210,939	04-2001	Gregory et al.
US- 5,824,544	10-1998	Armentano et al.
US- 2004/0087027 A1	05-06-2004	Gregory et al.

Foreign Patent Documents

<u>Document No.</u> <u>Publication Date</u>		<u>Patentee</u>	
WO 97/00326	01-03-1997	Introgene B.V.	
EP 0 117 060	08-29-84	Genentech, Inc.	

Serial No.: 10/038,271

Respectfully submitted,

Bretton L. Crockett Registration No. 44,632

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: November 5, 2004

BLC/alb

Enclosures: Form PTO-1449 or PTO/SB/08

Copy of documents cited

Document in ProLaw

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Of

Sheet

Examiner	Cite No.		Publication Date	Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials *			MM-DD-YYYY		
		US- 6,051,430	04-18-2000	Plasterk et al.	
	-	US- 6,140,103	10-31-2000	Einerhand et al.	
		US- 6,204,052	03-20-2001	Bout et al.	
		US- 6,232,105	05-15-2001	Einerhand et al.	
		US- 6,238,893	05-29-2001	Hoeben et al.	
		US- 6,265,212	07-24-2001	Fallaux et al.	
		US- 6,203,975	03-2001	Wilson	
		US- 6,306,652 B1	10-23-2001	Fallaux et al.	
		US- 6,602,706 B1	08-05-2003	Fallaux et al.	
		US- 2002/0102732 A1	08-01-2002	Fallaux et al.	
		US- 2002/0173039 A1	11-02-2002	Fallaux et al.	
		US- 2003/0104626 A1	06-05-2003	Fallaux et al.	
		US- 2002/0164802 A1	11-07-2002	Fallaux et al.	
		US- 6,210,939	04-2001	Gregory et al.	
		US- 5,824,544	10-1998	Armentano et al.	
		US- 2004/0087027 A1	05-06-2004	Gregory et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY			
		WO 97/00326	01-03-1997	Introgene B.V.		
		EP 0 117 060	08-29-84	Genentech, Inc.		_
	<u> </u>	-				

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional) . ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.